部分男性从前列腺切除术后挽救性放疗联合雄激素剥夺治疗中获益
该研究纳入1987至2010年间332例前列腺切除术后接受挽救性放疗(SRT)的患者,用递归分区分析(RPA)分为预后良好、中等和不良三组。结果显示,在SRT基础上加用雄激素剥夺治疗(ADT)可改善预后不良组和中等组的5年无失败生存(FFS),但对预后良好组无显著获益;作者认为结果仅用于生成假设,需进一步前瞻性数据验证。
要点
- RPA将术后SRT患者分为预后良好、中等和不良三组,不良因素为手术切缘阴性及放疗前PSA≥0.5 ng/ml。
- 加用ADT改善预后不良组5年FFS(70.3% vs 23.4%,P<0.001)和中等组(69.8% vs 48.0%,P=0.003)。
- 预后良好组加用ADT未见5年FFS显著获益(81.2% vs 78.0%,P=0.971)。
核心结论
- 在SRT基础上加用ADT似乎可改善放疗前PSA≥0.5 ng/ml或手术切缘阴性男性的FFS。
- 手术切缘阳性且PSA<0.5 ng/ml的男性单独SRT后失败风险较低,加用ADT的获益可能较小。
- 作者指出上述结果仅用于生成假设,需进一步前瞻性数据验证该选择人群能否安全省略ADT。
研究设计与样本
- 研究纳入1987至2010年间接受前列腺切除术后SRT的332例男性。
- 采用递归分区分析(RPA)依据单独SRT后失败风险分为预后良好、中等和不良三组。
- 采用Kaplan-Meier法和log-rank检验比较加用与不加用ADT的FFS。
主要发现
- 43%接受单独SRT,57%接受SRT联合ADT,ADT中位疗程6.6个月(四分位距5.8-18.1)。
- SRT中位剂量70 Gy(四分位距70-70),SRT后中位随访6.7年(四分位距4.5-10.8)。
- Cox比例风险回归显示ADT改善FFS(校正风险比0.60,95%置信区间0.42-0.86;P=0.006)。
- 预后不良组加用ADT的5年FFS为70.3% vs 23.4%(P<0.001),中等组为69.8% vs 48.0%(P=0.003)。
- 预后良好组加用ADT的5年FFS为81.2% vs 78.0%(P=0.971),无显著差异。
关键数值与推荐
- RPA将预后不良定义为手术切缘阴性且放疗前PSA≥0.5 ng/ml。
- 预后良好定义为不具备上述两项不良因素,中等定义为具备其中一项不良因素。
临床怎么用
- 作者认为结果仅用于生成假设,需进一步前瞻性数据验证该选择人群能否安全省略ADT。
局限性
- 作者指出结果仅用于生成假设,需进一步前瞻性数据验证该选择人群能否安全省略ADT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Which men benefit most from adding androgen deprivation therapy (ADT) to salvage radiation therapy (SRT) after prostatectomy has not clearly been defined; therefore, we evaluated the impact of ADT to SRT on failure-free survival (FFS) in men with a rising or persistent PSA after prostatectomy. METHODS: We identified 332 men who received SRT after prostatectomy from 1987 to 2010. Recursive partitioning analysis (RPA) identified favorable, intermediate and unfavorable groups based on the risk of failure after SRT alone. Kaplan-Meier and log-rank tests compared FFS with and without ADT. RESULTS: Forty-three percent received SRT alone and 57% received SRT with ADT (median 6.6 months (interquartile range (IQR) 5.8-18.1) ADT). Median SRT dose was 70 Gy (IQR 70-70), and median follow-up after SRT was 6.7 years (IQR 4.5-10.8). On Cox's proportional hazard regression, ADT improved FFS (adjusted hazard ratio 0.60, 95% confidence interval: 0.42-0.86; P=0.006). RPA classified unfavorable disease as negative surgical margins (SMs) and preradiation PSA of ⩾0.5 ng ml-1. Favorable disease had neither adverse factor, and intermediate disease had one adverse factor. The addition of ADT to SRT improved 5-year FFS for men with unfavorable disease (70.3% vs 23.4%; P<0.001) and intermediate disease (69.8% vs 48.0%; P=0.003), but not for men with favorable disease (81.2% vs 78.0%; P=0.971). CONCLUSIONS: The addition of ADT to SRT appears to improve FFS for men with a preradiation PSA of ⩾0.5 ng ml-1 or with negative SM at prostatectomy. Men with involved surgical margins and PSA <0.5 ng ml-1 appear to be at a lower risk of failure after SRT alone and may not derive as much benefit from the administration of ADT with SRT. These results are hypothesis-generating only, and further prospective data are required to see if ADT can safely be omitted in this select group of men.
引用
- Holliday EB, Kuban DA, Levy LB, et al. Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy. Prostate Cancer Prostatic Dis. 2017. PMID: 28462945. doi:10.1038/pcan.2017.24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。